Skip to main content
CDT
NASDAQ Life Sciences

CDT Equity Amends ELOC & Convertible Note with Unfavorable Terms

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$1.725
Mkt Cap
$8.381M
52W Low
$1.691
52W High
$1,224
Market data snapshot near publication time

summarizeSummary

CDT Equity Inc. amended its Equity Line of Credit and a convertible note, agreeing to a $510,000 purchase and diverting 10% of future capital raises to debt repayment under terms effective only until May 31, 2026.


check_boxKey Events

  • Equity Line of Credit Amended

    The company amended its directed stock purchase agreement, setting a gross purchase price of $510,000 for regular purchases and extending an 'Adjustment Period' that could result in additional dilutive share issuances if the stock price drops after the investor's purchase.

  • Convertible Note Amended

    An amendment to a Senior Secured Convertible Promissory Note now requires 10% of all future debt or equity financing proceeds, including from the ELOC, to be used for repayment of the note.

  • Short-Term Effectiveness

    Both amendments are only effective through May 31, 2026, indicating a very short-term financial arrangement.

  • Going Concern Context

    These highly dilutive and unfavorable financing terms come after the company's recent 10-K filing disclosed substantial doubt about its ability to continue as a going concern.


auto_awesomeAnalysis

CDT Equity Inc. has amended its Equity Line of Credit (ELOC) and a Senior Secured Convertible Promissory Note. The ELOC amendment sets a gross purchase price of $510,000 for regular purchases and extends an 'Adjustment Period' which could lead to further dilution if the stock price declines after the investor's purchase. The Convertible Note amendment mandates that 10% of all future debt or equity financing proceeds, including from the ELOC, must be used to repay the note. These amendments, effective only until May 31, 2026, represent a short-term and costly capital raise for a company that recently disclosed substantial doubt about its ability to continue as a going concern. The terms are highly unfavorable, diverting much-needed capital to debt repayment and exposing shareholders to significant potential dilution.

At the time of this filing, CDT was trading at $1.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $1.69 to $1,224.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CDT - Latest Insights

CDT
May 15, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
CDT
May 14, 2026, 8:47 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
CDT
May 06, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CDT
May 01, 2026, 5:11 PM EDT
Filing Type: 424B3
Importance Score:
9
CDT
Apr 21, 2026, 9:56 PM EDT
Filing Type: S-3
Importance Score:
9
CDT
Apr 15, 2026, 5:01 PM EDT
Filing Type: 10-K
Importance Score:
9
CDT
Apr 02, 2026, 4:15 PM EDT
Filing Type: 424B5
Importance Score:
9
CDT
Mar 30, 2026, 9:21 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
CDT
Mar 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CDT
Mar 25, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8